Question 1

How does measles spread?

Accepted Answer

Measles is one of the most contagious infectious diseases known. It spreads through the air via tiny respiratory aerosols and droplets released when an infected person coughs, sneezes, or breathes. The virus can survive in the air and on surfaces for up to 2 hours after an infected person has left a room — meaning you can catch measles without direct contact. The basic reproduction number (R₀) is 12–18: each infectious person can infect 12 to 18 unvaccinated contacts in a susceptible population. An infected person is contagious from about 4 days before their rash appears through 4 days after — roughly 8 days total, often before they know they are sick. Measles has no animal reservoir, which means it can only survive by continuously infecting people. This makes herd immunity — achieved through ≥95% two-dose MMR vaccination — the only sustainable way to stop transmission.

Question 2

Is measles back in 2026?

Accepted Answer

Yes — measles is back in the United States and in several other countries in 2026. The US is experiencing its largest measles resurgence in decades: over 2,104 confirmed cases were reported to the CDC by mid-2026, surpassing every annual total since before the disease was declared eliminated in 2000. The outbreak is driven entirely by communities with low two-dose MMR vaccination coverage, not by a change in the virus itself. The measles virus (Measles morbillivirus) is genetically unchanged and the MMR vaccine remains highly effective (97% with two doses). States most affected include Texas, Montana, and others where pockets of unvaccinated individuals allowed the virus to sustain chains of transmission. Globally, WHO reports active outbreaks in Romania, Italy, the Democratic Republic of Congo, and several countries in sub-Saharan Africa and Southeast Asia in 2025–2026. Measles is not 'back' as an endemic pathogen in the USA — elimination status is maintained as long as no continuous year-round chain of domestic transmission is established — but the current outbreak is a serious public-health warning about the consequences of falling vaccination rates.

Question 3

Is there a measles outbreak in the USA in 2025–2026?

Accepted Answer

Yes. The United States is experiencing a significant measles resurgence in 2025–2026, with case counts reaching levels not seen since 2019. Outbreaks have been concentrated in communities with low MMR vaccination rates — particularly among unvaccinated children and adults in states including Texas, Montana, and others. Measles was declared eliminated from the USA in 2000, meaning there is no longer sustained year-round transmission; however, outbreaks still occur when unvaccinated travelers import the virus and it spreads through under-immunized pockets of the population. The CDC monitors all cases and recommends two-dose MMR vaccination as the primary prevention measure. International travel to countries with active measles transmission increases exposure risk for unvaccinated individuals. Parents should confirm their children have received two MMR doses on schedule; adults who are unsure of their vaccination history should consult a physician.

Question 4

When is a person with measles contagious?

Accepted Answer

A person with measles is contagious from approximately 4 days before the rash appears through 4 days after rash onset — a total infectious window of about 8 days. This means an infected person is spreading measles before they even know they have it, since the rash does not appear until the disease has been progressing for several days. During the prodromal phase (before the rash), the only symptoms are fever, cough, runny nose, and red eyes — easily mistaken for a common cold or flu. This pre-rash contagiousness is one of the main reasons measles outbreaks are so hard to contain: by the time someone is diagnosed, they may have already exposed many others. People with measles should be isolated from others from 4 days before rash onset through 4 days after rash onset, per CDC guidelines.

Question 5

What are the symptoms of measles?

Accepted Answer

Measles begins with 3–4 days of high fever (often above 40°C/104°F), cough, runny nose (coryza), and red, watery eyes (conjunctivitis) — known as the '3 Cs'. A key early sign is Koplik's spots: tiny white or grey-blue dots on the inside of the cheeks, appearing 1–2 days before the rash and pathognomonic (unique) to measles. The hallmark maculopapular rash then starts at the hairline and face, spreading downward to the trunk and limbs over 3 days. Fever peaks when the rash appears, then gradually falls if the illness is uncomplicated. Complications include ear infections (about 1 in 10 children), pneumonia (the leading cause of measles deaths), and, rarely, encephalitis (1–2 per 1,000 cases). A lesser-known long-term risk is immune amnesia: measles can wipe out 11–73% of existing antibody memory for 2–3 years, leaving recovered individuals more susceptible to other infections.

Question 6

Is there a treatment or cure for measles?

Accepted Answer

There is no approved specific antiviral drug for measles. Treatment is supportive — meaning it aims to reduce symptoms and prevent complications rather than directly kill the virus. Key elements include: adequate hydration, fever management with acetaminophen or ibuprofen (never aspirin in children), and vitamin A supplementation — WHO recommends two high-dose vitamin A doses for all children with measles, as it has been shown to significantly reduce measles mortality and the severity of complications including blindness and pneumonia. Secondary bacterial infections (the most common cause of measles-related deaths in both children and adults) are treated with appropriate antibiotics. Severe pneumonia and measles encephalitis require hospitalization and may need intensive care. The best 'treatment' remains prevention: two doses of MMR vaccine before exposure provide lifelong protection in ~97% of recipients.

Question 7

How effective is the measles (MMR) vaccine?

Accepted Answer

The MMR (measles-mumps-rubella) vaccine is highly effective. A single dose provides approximately 93% protection against measles; two doses provide approximately 97% protection. The two-dose schedule — first at 12–15 months, second at 4–6 years — is the global standard recommended by WHO and CDC and is why measles was declared eliminated from the USA in 2000. Protection from two doses is generally lifelong for the vast majority of vaccinated people. Adults born before 1957 are presumed immune from prior natural infection. Adults born in 1957 or later who haven't had measles or received two vaccine doses should get vaccinated. The 2025–2026 USA resurgence is driven entirely by communities with low two-dose MMR coverage — not by the vaccine failing, but by vaccination gaps allowing the virus to find susceptible hosts.

Measles

Strains

Transmission

Symptoms

Prodromal phase — days 1–4 before rash

Exanthematous phase — days 4–7 rash

Complications — higher risk in <5 years, adults, immunocompromised, malnourished

Treatment

Vaccine status

Endemic regions

Frequently asked questions

Sources